Journal Article

Cost-Effectiveness of Risperidone, Olanzapine, and Conventional Antipsychotic Medications

Jeanette M. Jerrell

in Schizophrenia Bulletin

Published on behalf of Maryland Psychiatric Research Center

Volume 28, issue 4, pages 589-605
Published in print January 2002 | ISSN: 0586-7614
Published online January 2002 | e-ISSN: 1745-1701 | DOI:
Cost-Effectiveness of Risperidone, Olanzapine, and Conventional Antipsychotic Medications

More Like This

Show all results sharing this subject:

  • Child and Adolescent Psychiatry


Show Summary Details


To assess the cost and effectiveness of risperidone, olanzapine, and conventional antipsychotic medications under “usual practice” conditions in a large, public mental health system, 108 persons diagnosed with schizophrenia or schizoaffective disorder were randomly assigned to one of these three medication groups and followed prospectively over a 12-month period using standard instruments and procedures. Psychiatric medication costs increased more over time in both the olanzapine and risperidone groups than in the conventional medication group. Compliance with the prescribed medication was higher in the olanzapine group than in the conventional group. No differential effects by medication group were evident in this sample on the symptoms of schizophrenia, side effects, psychosocial functioning, time to discharge for index hospitalization, survival to initial rehospitalization, or client satisfaction with services. These results extend findings from previous efficacy and naturalistic studies in several ways but are limited chiefly by the small number of subjects who completed 6 to 12 months of the clinical trial, and the resulting power to detect differences in the statistical analyses.

Keywords: Schizophrenia; cost-effectiveness; risperidone; olanzapine; symptomatology outcomes; functioning outcomes

Journal Article.  0 words. 

Subjects: Child and Adolescent Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.